Inovio Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
INO Inovio Pharmaceuticals Inc
BAC Bank of America Corp
DGRW WisdomTree U.S. Quality Dividend Growth Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DFP Flaherty & Crumrine Dynamic Preferred and Income Fund
DES WisdomTree U.S. SmallCap Dividend Fund
DEO Diageo PLC
DDF Delaware Investments Dividend and Income Fund
DAL Delta Air Lines Inc
D Dominion Energy Inc
Go

Health Care : Biotechnology | Mid Cap Blend
Company profile

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Premarket

Last Trade
Delayed
$21.24
0.31 (1.48%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$20.93
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
3,350

10-day average volume:
88,421,776
3,350

Barbuto & Johansson, P.A. Reminds Investors of Today's Deadline in the Inovio Pharmaceuticals Class Action and Encourages Shareholders with Losses Exceeding $100,000 to Contact the Firm

2:05 am ET May 12, 2020 (Globe Newswire) Print

Barbuto & Johansson, P.A. ("BARJO") reminds investors that today is the last day to contact the Firm to learn more about the class action filed against Inovio Pharmaceuticals, Inc. (NASDAQGS: INO), and appointment of lead plaintiff.

The class action, McDermid v. Inovio Pharmaceuticals, Inc., et al., 2:20-cv-01402, was filed in the US District Court for the Eastern District of Pennsylvania on behalf of shareholders who purchased Inovio securities between February 14, 2020 and March 9, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages against Inovio and certain executives for alleged violations of federal securities laws.

Specifically, the lawsuit alleges that during the Class Period, the Inovio defendants capitalized on widespread COVID-19 fears by falsely claiming that Inovio had developed a vaccine for COVID-19. On the last day of the class period, when Citron Research exposed such misstatements, calling for an SEC investigation into the Company's claims, the stock price plummeted. Shareholders have until May 12, 2020 to seek appointment as lead plaintiff.

If you've suffered damages from investing in Inovio and would like to discuss your options, including petitioning the court for a leadership position, you may, without obligation or cost to you, contact the Firm's Managing Partner, Anthony Barbuto, at (888) 715-2520 or via email at anthony@barjolaw.com.

BARJO follows the principles set forth in the case Berger v. Compaq, 257 F.3d 475 (5th Cir, 2001) which states "[c]lass action lawsuits are intended to serve as a vehicle for capable, committed advocates to pursue the goals of the class members through counsel, not for capable, committed counsel to pursue their own goals through the class members." BARJO believes strongly that the choice of qualified lead plaintiff(s) can have a significant impact on the successful outcome of a case. If you wish to be considered to serve as lead plaintiff, you must request this position by application to the Court by today. BARJO recommends shareholders with losses exceeding $100,000 to contact the Firm.

Barbuto & Johansson, P.A.

Anthony Barbuto, Esq.

1-888-715-2520

12773 Forest Hill Blvd., 101

Wellington, FL 33414

www.barjolaw.com

__GNW8366DE3E__IMG

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.